Literature DB >> 23520183

Guidelines for the management of breakthrough pain in patients with cancer.

Augusto Caraceni1, Andrew Davies, Philippe Poulain, Hernán Cortés-Funes, Sunil J Panchal, Guido Fanelli.   

Abstract

The moral imperative to adequately manage pain is being increasingly recognized worldwide. A comprehensive pain management approach that addresses the various presentations of pain in patients with cancer is required, including appropriate management of breakthrough pain. Breakthrough pain commonly occurs in patients with advanced cancer and is disabling to the individual and burdensome to society, yet it is often inadequately managed. Because pain is heterogeneous, the best management of an individual's pain, including breakthrough pain in cancer, requires a thorough assessment to tailor the treatment strategies. Recently developed guidelines support this approach and recommend treating breakthrough pain using rapid- or short-acting opioids with pharmacodynamics that mirror the rapid onset and short duration of the presenting pain. This approach should be part of a comprehensive strategy to treat pain within the context of the primary disease trajectory, offering continuity of care and access to specialized palliative care when appropriate.

Entities:  

Mesh:

Year:  2013        PMID: 23520183     DOI: 10.6004/jnccn.2013.0211

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  12 in total

1.  Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON).

Authors:  J Porta-Sales; C Pérez; Y Escobar; V Martínez
Journal:  Clin Transl Oncol       Date:  2015-12-22       Impact factor: 3.405

2.  Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study.

Authors:  R López López; C Camps Herrero; P Khosravi-Shahi; V Guillem Porta; A Carrato Mena; J Garcia-Foncillas; J J Cruz Hernández; P Gascón Vilaplana; A Antón Torres; E Diaz-Rubio; M Feyjoo Saus; E Aranda Aguilar
Journal:  Clin Transl Oncol       Date:  2017-10-03       Impact factor: 3.405

Review 3.  Multidimensional Treatment of Cancer Pain.

Authors:  Weiyang Christopher Liu; Zhong Xi Zheng; Kian Hian Tan; Gregory J Meredith
Journal:  Curr Oncol Rep       Date:  2017-02       Impact factor: 5.075

4.  Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures.

Authors:  J Pardo; A Mena; E Jiménez; N Aymar; I Ortiz; R Roncero; F Mestre; M Vidal
Journal:  Clin Transl Oncol       Date:  2019-05-15       Impact factor: 3.405

5.  Canadian recommendations for the management of breakthrough cancer pain.

Authors:  P Daeninck; B Gagnon; R Gallagher; J D Henderson; Y Shir; C Zimmermann; B Lapointe
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

6.  A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.

Authors:  Kazuhiko Koike; Takeshi Terui; Tomokazu Nagasako; Iori Horiuchi; Takayuki Machino; Toshiro Kusakabe; Yasuo Hirayama; Hiroyoshi Mihara; Michiaki Yamakage; Junji Kato; Takuji Nishisato; Kunihiko Ishitani
Journal:  Support Care Cancer       Date:  2015-08-07       Impact factor: 3.603

7.  A fixed inhaled nitrous oxide/oxygen mixture as an analgesic for adult cancer patients with breakthrough pain: study protocol for a randomized controlled trial.

Authors:  Qiang Liu; Yu Wang; Xiang-Jiang Luo; Ning-Ju Wang; Ping Chen; Xin Jin; Guo-Xia Mu; Xiao-Min Chai; Yue-Juan Zhang; Yu-Xiang Li; Jian-Qiang Yu
Journal:  Trials       Date:  2017-01-11       Impact factor: 2.279

Review 8.  The Basic Pharmacology of Opioids Informs the Opioid Discourse about Misuse and Abuse: A Review.

Authors:  Joseph V Pergolizzi; Jo Ann LeQuang; Garrett K Berger; Robert B Raffa
Journal:  Pain Ther       Date:  2017-03-24

9.  Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.

Authors:  Masoud Hashemi; Alireza Zali; Ebrahim Golmakani; Mohammad Hossein Delshad; Mahdi Shadnoush; Mohammad-Esmaeil Akbari
Journal:  Daru       Date:  2021-01-21       Impact factor: 3.117

10.  Management of predictable pain using fentanyl pectin nasal spray in patients undergoing radiotherapy.

Authors:  Brent C Bell; E Brian Butler
Journal:  J Pain Res       Date:  2013-12-11       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.